risperidone has been researched along with Sleep Wake Disorders in 15 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 9.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "Risperidone has been reported as a well-tolerated antipsychotic in children." | 5.35 | An unreported side effect of risperidone in children: sinus arrest with long pauses causing syncope. ( Ceviz, N; Karacan, M; Olgun, H; Sepetcigil, O, 2009) |
| " The primary objective of this double-blind study was to compare the effects of treatment initiation with risperidone and quetiapine on cognitive function in subjects with stable bipolar disorder." | 5.12 | Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. ( Engelhart, LM; Gharabawi, GM; Harvey, PD; Hassman, H; Mahmoud, RA; Mao, L, 2007) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 5.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| ", weight gain, liver function, extrapyramidal side effects, and seizures) and efficacy of the long-term use of risperidone in children and adolescents and to ascertain the effects of drug withdrawal in a semi-naturalistic prospective, subjects with autism or pervasive developmental disorders not otherwise specified (PDDNOS) were treated with risperidone for 6 months after which parents were given the option of continuing for a further 6 months (final assessment at 12 months)." | 5.09 | Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. ( Cianchetti, C; Di Martino, A; Muglia, P; Zuddas, A, 2000) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "DSM-IV PTSD diagnoses were made by using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Nonpatient Edition." | 2.82 | Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504. ( Collins, J; Cramer, JA; Huang, GD; Jones, KM; Krystal, AD; Krystal, JH; Pietrzak, RH; Rosenheck, RA; Vertrees, JE; Vessicchio, J, 2016) |
| "Risperidone-treated patients had a significantly greater reduction in total score on the CAPS-2 (z = -2." | 2.71 | A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. ( Hennen, J; Reich, DB; Stanculescu, C; Watts, T; Winternitz, S, 2004) |
| "Risperidone has been reported as a well-tolerated antipsychotic in children." | 1.35 | An unreported side effect of risperidone in children: sinus arrest with long pauses causing syncope. ( Ceviz, N; Karacan, M; Olgun, H; Sepetcigil, O, 2009) |
| "When treated with risperidone 2 mg/day, both his sleep and the delusional thoughts improved markedly and his daytime alertness increased." | 1.30 | Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. ( Gross, Y; Klag, E; Pick, CG; Schreiber, S; Segman, RH, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, S | 1 |
| Chik, I | 1 |
| Wilson, BA | 1 |
| Anagnostou, E | 1 |
| Yin, Y | 1 |
| Liu, Y | 1 |
| Zhuang, J | 1 |
| Pan, X | 1 |
| Li, P | 1 |
| Yang, Y | 1 |
| Li, YP | 1 |
| Zhao, ZQ | 1 |
| Huang, LQ | 1 |
| Zhao, ZX | 1 |
| Krystal, JH | 1 |
| Pietrzak, RH | 1 |
| Rosenheck, RA | 1 |
| Cramer, JA | 1 |
| Vessicchio, J | 1 |
| Jones, KM | 1 |
| Huang, GD | 1 |
| Vertrees, JE | 1 |
| Collins, J | 1 |
| Krystal, AD | 1 |
| Arana-Lechuga, Y | 1 |
| Sanchez-Escandón, O | 1 |
| de Santiago-Treviño, N | 1 |
| Castillo-Montoya, C | 1 |
| Terán-Pérez, G | 1 |
| Velázquez-Moctezuma, J | 1 |
| Olgun, H | 1 |
| Sepetcigil, O | 1 |
| Karacan, M | 1 |
| Ceviz, N | 1 |
| Reich, DB | 1 |
| Winternitz, S | 1 |
| Hennen, J | 1 |
| Watts, T | 1 |
| Stanculescu, C | 1 |
| Mulsant, BH | 1 |
| Gharabawi, GM | 2 |
| Bossie, CA | 1 |
| Mao, L | 2 |
| Martinez, RA | 1 |
| Tune, LE | 1 |
| Greenspan, AJ | 1 |
| Bastean, JN | 1 |
| Pollock, BG | 1 |
| Uchimura, N | 1 |
| Kotorii, N | 1 |
| McEvoy, JP | 1 |
| Lieberman, JA | 1 |
| Perkins, DO | 1 |
| Hamer, RM | 1 |
| Gu, H | 1 |
| Lazarus, A | 1 |
| Sweitzer, D | 1 |
| Olexy, C | 1 |
| Weiden, P | 1 |
| Strakowski, SD | 1 |
| Harvey, PD | 1 |
| Hassman, H | 1 |
| Mahmoud, RA | 1 |
| Engelhart, LM | 1 |
| Schreiber, S | 1 |
| Klag, E | 1 |
| Gross, Y | 1 |
| Segman, RH | 1 |
| Pick, CG | 1 |
| Hori, M | 1 |
| Shiraishi, H | 1 |
| Zuddas, A | 1 |
| Di Martino, A | 1 |
| Muglia, P | 1 |
| Cianchetti, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder[NCT00099983] | Phase 2 | 296 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.[NCT01917318] | Phase 2 | 1 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to Enrollment challenges - Single participant discontinued after placebo, no relevant outcome measure data was recorded.) | ||
| Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison[NCT00034892] | Phase 3 | 0 participants | Interventional | 2002-03-31 | Completed | ||
| Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients.[NCT00097032] | Phase 3 | 30 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure for this study was the total score on the 34-item Clinician-Administered PTSD Scale (CAPS). This study was the intent-to-treat analysis of the improvement in PTSD symptoms from baseline to week-24 follow-up as measured by the CAPS. Total score range for the CAPS is 0-136 with higher values representing a worse outcome. This study was powered initially to detect a 9-point difference between the treatment groups in the CAPS change score. (NCT00099983)
Timeframe: 24 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Risperidone | -16.3 |
| Sugar Pill | -12.5 |
"Intensity of Suicidal Ideation was monitored over the course of the trial by the second section of the Columbia Suicide Severity Rating Scale (CSSRS). This section is only administered if the patient answers yes to the first section. The section consists of 5 questions that refer to the most severe level of ideation endorsed in the first section of the CSSRS. The total score ranges from 2 to 25, with a higher number indicating more intense ideation and greater risk.~Only lifetime intensity of suicidal ideation was explored as the patient had no suicidal ideation from the month prior to beginning the study to the completion of the study" (NCT01917318)
Timeframe: Baseline
| Intervention | score on a scale (Number) |
|---|---|
| Placebo / Iloperidone | 16 |
Aggression was measured by the Modified Overt Aggression Scale (MOAS).This assessment measures four types of aggressive behavior (verbal, aggression against property, autoaggression, and physical aggression) . Total scores on the MOAS range from 0-40, with a higher score indicating more aggressive behavior. (NCT01917318)
Timeframe: Randomization and 8 weeks of treatment, during both treatment periods
| Intervention | units on a scale (Number) | |||
|---|---|---|---|---|
| MOAS at randomization 1 | MOAS after 8 weeks with placebo | MOAS at randomization 2 | MOAS after 2 weeks with iloperidone treatment | |
| Placebo / Iloperidone | 1 | 0 | 0 | 0 |
"The Clinician-Administered PTSD Scale (CAPS) is a structured interview used to diagnose and assess PTSD. Part B of CAPS evaluates symptoms of re-experiencing. Part D evaluates avoidance and numbing.~CAPS-B scores range from 0 to 40 where higher scores indicate more symptoms. A score 0 means no re-experiencing symptoms.~CAPS-D scores range form 0 to 56 and higher scores indicate more symptoms. A score 0 means no avoidance or numbing symptoms.~The primary endpoint was changes in CAPS part B and D after 8 weeks of treatment." (NCT01917318)
Timeframe: Randomization and at the end of each treatment period. Placebo treatment lasted 8 weeks. Iloperidone treatment lasted 2 weeks.
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| CAPS part B at randomization 1 | CAPS part B after 8 weeks with placebo | CAPS part B at randomization 2 | CAPS part B after 2 weeks with iloperidone | CAPS part D at randomization 1 | CAPS part D after 8 weeks with placebo | CAPS part D at randomization 2 | CAPS part D after 2 weeks with iloperidone | |
| Placebo / Iloperidone | 20 | 4 | 4 | 0 | 6 | 2 | 7 | 0 |
The presence and severity os suicidal behavior was monitored over the course of the trial by the third section of the Columbia Suicide Severity Rating Scale (CSSRS). This sections consists of questions about 5 suicidal behaviors and non-suicidal self injurious behavior and it can be answered yes or no. The number of participants who experienced suicidal behavior is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal behavior | 1 month prior ro screening | During the course of the study | |
| Placebo / Iloperidone | 0 | 0 | 0 |
The presence of suicidal ideation was monitored over the course of the trial by the first section of the Columbia Suicide Severity Rating Scale (CSSRS). This first section of the scale consists of 5 questions that can be answered yes or no. The number of participants who reported experiencing suicidal ideation is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal ideation | 1 month prior to screening | Suicidal ideation during the study | |
| Placebo / Iloperidone | 1 | 0 | 0 |
2 reviews available for risperidone and Sleep Wake Disorders
| Article | Year |
|---|---|
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
7 trials available for risperidone and Sleep Wake Disorders
| Article | Year |
|---|---|
Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Caregivers; Donepezil; Female; Hum | 2015 |
Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504.
Topics: Adult; Aged; Combat Disorders; Double-Blind Method; Female; Humans; Interview, Psychological; Male; | 2016 |
A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Child; Child Abuse; Child Abuse, Sexual; D | 2004 |
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorders; Delusions; Demen | 2004 |
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; D | 2007 |
Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study.
Topics: Adult; Antipsychotic Agents; Attention; Bipolar Disorder; Cognition; Cognition Disorders; Dibenzothi | 2007 |
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Female; Humans; Male; Psychiatric Status | 2000 |
6 other studies available for risperidone and Sleep Wake Disorders
| Article | Year |
|---|---|
Paranoid delusions • ideas of reference • sleep problems • Dx?
Topics: Antipsychotic Agents; Asian People; Delusions; Female; Humans; Late Onset Disorders; Middle Aged; Pr | 2020 |
Risperidone treatment of sleep disturbances in Tourette's syndrome.
Topics: Antipsychotic Agents; Child; Electroencephalography; Humans; Male; Neuropsychological Tests; Risperi | 2008 |
An unreported side effect of risperidone in children: sinus arrest with long pauses causing syncope.
Topics: Antipsychotic Agents; Child; Diagnosis, Differential; Dose-Response Relationship, Drug; Electrocardi | 2009 |
[Sleep disorders in schizophrenic patients and the effect of atypical antipsychotic agents].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Mal | 2006 |
Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury.
Topics: Antipsychotic Agents; Brain Injuries; Circadian Rhythm; Humans; Male; Middle Aged; Psychotic Disorde | 1998 |
Risperidone-induced anxiety might also develop 'awakening' phenomenon.
Topics: Adult; Antipsychotic Agents; Anxiety; Humans; Male; Risperidone; Schizophrenia, Paranoid; Sleep Wake | 1999 |